#TNBC

In a medical research laboratory half a world away from Thailand, Australian scientists have uncovered potentially life-saving evidence that inexpensive heart medications already sitting in millions of Thai medicine cabinets might hold the key to fighting the most aggressive and treatment-resistant form of breast cancer. This groundbreaking discovery could revolutionize cancer care for thousands of Thai women who face devastating diagnoses of triple-negative breast cancer, a particularly lethal disease subtype that has historically offered few treatment options and claimed countless lives across Southeast Asia.

A new laboratory study suggests cheap beta-blocker drugs can slow the spread of triple-negative breast cancer.
The finding could change treatment strategies for a hard-to-treat cancer subtype worldwide. ( Monash University press release )

Triple-negative breast cancer, or TNBC, lacks three common receptors.
Doctors find TNBC hard to treat with hormone or HER2-targeted therapies. ( World Journal review on TNBC prevalence and challenges )

The Monash University team studied how beta-2 adrenoceptor signals drive TNBC invasion.
They found a regulatory gene called HOXC12 helps couple the receptor to pro-invasion signals. ( Monash University press release )

A groundbreaking advancement in cancer prevention has emerged through the development of a vaccine aimed at halting triple-negative breast cancer (TNBC) before it even begins. This promising development deepens our understanding of how proactive immunological defenses can target aggressive forms of cancer. TNBC is notably difficult to treat, and this new vaccine—resulting from a collaboration between Anixa Biosciences and the Cleveland Clinic—marks a significant step forward in preventing this challenging condition.